Pierre A. Geoffroy, MD, PhD

  • 6Articles
  • 40.4KReads
  • 2022–2025Active
  • 33Collaborators
  • 66Citations

About

Pierre A. Geoffroy, MD, PhD, is affiliated with multiple institutions in France, including the Département de Psychiatrie et d’Addictologie at AP-HP, GHU Paris Nord, Université Paris Cité, Inserm, Centre ChronoS, and Strasbourg University. His research focuses on suicide risk, addiction, bipolar disorder, and sleep disturbances. Geoffroy has published studies on interventions such as bright light therapy for bipolar depression, the relationship between sleep alterations and suicide risk, and the impact of orexin receptor antagonists on suicidal behaviors. His work often explores clinical markers and risk factors associated with psychiatric disorders and suicide.

Publications

JCP
Bright Light Therapy in the Morning or Midday for Nonseasonal Depression in Bipolar Disorder
Original Research

Bright Light Therapy in the Morning or Midday for Nonseasonal Depression in Bipolar Disorder

June 23, 2025

Bright light therapy is well tolerated in bipolar disorder, starting at 45 minutes/day, with only 6% of patients experiencing a hypomanic switch and 13% experiencing subsyndromic symptoms, which resolved...
, , , et al
JCP
Sleep Alterations as Proximal Markers for Suicide Risk
Commentary

Sleep Alterations as Proximal Markers for Suicide Risk

June 3, 2024

Dr Geoffroy discusses recent research exploring the links between suicide and sleep disturbances.
JCP
Dual Orexin Receptor Antagonists and Suicide Risk
Brief Report

Dual Orexin Receptor Antagonists and Suicide Risk

September 27, 2023

According to the WHO pharmacovigilance database, suicidal behavior was 1.3 times more frequent than expected with dual orexin receptor antagonists and 4.7 times more frequent for Z-drugs; data on...
, , , et al
JCP
Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link
Letter to the Editor

Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link

July 3, 2023

Palagini and colleagues comment on a recent letter that suggested a role for daridorexant, a new hypnotic, in increasing suicide risk.
, , , et al
JCP
Sleep Complaints and Risk of Psychiatric Disorders
Original Research

Sleep Complaints and Risk of Psychiatric Disorders

December 21, 2022

Sleep complaints were associated with risk of psychiatric disorders independent of sociodemographic and clinical characteristics in this study of NESARC data.
, , , et al
JCP
Bad Dreams and Nightmares Preceding Suicidal Behaviors
Original Research

Bad Dreams and Nightmares Preceding Suicidal Behaviors

November 23, 2022

Suicidal behavior may be preceded by a sequence of altered dreams that goes from bad dreams to nightmares and finally to suicidal scenarios in dreams a few weeks before...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe